23.98
-0.50 (-2.04%)
| Previous Close | 24.48 |
| Open | 24.67 |
| Volume | 1,506,348 |
| Avg. Volume (3M) | 999,955 |
| Market Cap | 1,264,705,152 |
| Price / Sales | 4.21 |
| Price / Book | 4.91 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2024 |
| Profit Margin | -45.90% |
| Operating Margin (TTM) | -12.66% |
| Diluted EPS (TTM) | -2.69 |
| Quarterly Revenue Growth (YOY) | 23.40% |
| Total Debt/Equity (MRQ) | 10.97% |
| Current Ratio (MRQ) | 4.10 |
| Operating Cash Flow (TTM) | 7.78 M |
| Levered Free Cash Flow (TTM) | 19.38 M |
| Return on Assets (TTM) | -7.50% |
| Return on Equity (TTM) | -43.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | CareDx, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 3.45% |
| % Held by Institutions | 96.05% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (BTIG, 45.96%) | Buy |
| 35.00 (Goldman Sachs, 45.96%) | Buy | |
| Median | 35.00 (45.96%) | |
| Average | 35.00 (45.96%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 24.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 05 Nov 2024 | 35.00 (45.95%) | Buy | 22.90 |
| Goldman Sachs | 16 Oct 2024 | 35.00 (45.95%) | Buy | 26.18 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |